|Cerasomal-cis-9-cetylmyristoleate is the companies designation of their
Cetyl Myristoleate product. Despite the claims the company makes there is no evidence that
their product is any more effective than other Cetyl Myristoleate products.
CMO (Cerasomol-cis-9-Cetyl Myristoleate)
in the Treatment of Fibromyalgia: An Open Pilot Study.
||Journal of Nutritional & Environmental Medicine, Jun2001, Vol. 11 Issue 2, p105, 7p, 2 graphs
||Purpose: To investigate the efficacy and tolerability of CMO
(cerasomol-cis-9-cetyl myristoleate) in the treatment of fibromyalgia.:
Design: Open study: 21 days' treatment following a 7-day baseline without treatment.:
Materials and Methods: Thirteen adult patients with fibromyalgia. Following a 7-day
pre-treatment baseline, patients were treated with a mixture of CMO + sea cucumber and
shark cartilage extracts. All treatments were administered orally. Patients kept daily
diary cards recording the severity of generalized pain, fatigue and sleep disturbance
(scale 0-4). A symptom profile was made using an 84-point questionnaire. Adverse events
were recorded.: Results: Ten patients completed the study. One subject did not record
baseline symptoms. Two patients had to discontinue treatment because of adverse effects.
One had severe indigestion and the other developed muscle spasms and a skin rash. The mean
(SD) scores for the severity of pain, fatigue, and sleep disturbance during the baseline
were 2.63 (0.55), 2.50 (0.54) and 2.33 (0.480). These improved to 1.70 (0.82), 1.83 (0.82)
and 1.73 (1.11) during the last 7 days of treatment. There were individual differences in
response with five patients showing good response and five showing little or no response.
From the questionnaires those showing the best response had more severe pain and cognitive
dysfunction than the non-responders. In addition to the two withdrawals, one further
patient reported gastrointestinal symptoms.: Conclusions: This open study provides
evidence of a beneficial effect of CMO in the treatment of fibromyalgia. A double-blind,
placebo-controlled study is now required to confirm this. This should also include a
symptom profile questionnaire, which may help to distinguish responders and
non-responders. [ABSTRACT FROM AUTHOR]
|Full Text Word Count: